ARAVIVE (ARAV) Competitors $0.04 0.00 (0.00%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. ATNFW, LBPSW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, CALA, and CELUWShould you be buying ARAVIVE stock or one of its competitors? The main competitors of ARAVIVE include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), Calithera Biosciences (CALA), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. ARAVIVE vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Celularity ARAVIVE (NASDAQ:ARAV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Is ARAV or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets ARAVIVEN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer ARAV or ATNFW? In the previous week, ARAVIVE's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment ARAVIVE Neutral 180 Life Sciences Neutral Do institutionals & insiders believe in ARAV or ATNFW? 35.8% of ARAVIVE shares are owned by institutional investors. 60.4% of ARAVIVE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, ARAV or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than ARAVIVE. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARAVIVE$9.14MN/A-$76.32MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A SummaryARAVIVE beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks. Get ARAVIVE News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricARAVIVEMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E RatioN/A21.5785.4727.60Price / SalesN/A427.64582.22224.03Price / CashN/A47.1237.9261.55Price / BookN/A10.1413.136.76Net Income-$76.32M-$52.31M$3.30B$275.88M7 Day PerformanceN/A5.14%4.29%2.81%1 Month PerformanceN/A14.68%9.45%9.24%1 Year PerformanceN/A30.98%86.64%35.42% ARAVIVE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeATNFW180 Life SciencesN/A$0.08+13.4%N/A+873.0%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.14-20.2%N/A+380.0%$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.20-20.1%N/A-51.2%$0.00$560.10M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-22.8%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.10+3.1%N/A+312.0%$0.00$39.19M0.0070Positive NewsGap UpBTMDWbioteN/A$0.01+20.0%N/AN/A$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.03-7.4%N/A-87.1%$0.00N/A0.008Negative NewsGap UpCALACalithera BiosciencesN/AN/AN/A-95.0%$0.00N/A0.0060CELUWCelularityN/A$0.04-20.0%N/A+111.1%$0.00$44.59M0.00220Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARAVIVE, INC Please log in to your account or sign up in order to add this asset to your watchlist. Share ARAVIVE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
